DekaBank Deutsche Girozentrale Buys 1,023 Shares of Humana Inc. (HUM)
DekaBank Deutsche Girozentrale lifted its holdings in Humana Inc. (NYSE:HUM) by 1.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 54,192 shares of the insurance provider’s stock after purchasing an additional 1,023 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Humana were worth $13,560,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Reliance Trust Co. of Delaware increased its stake in shares of Humana by 0.7% in the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock worth $270,000 after purchasing an additional 8 shares during the period. Creative Planning increased its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after purchasing an additional 15 shares during the period. WFG Advisors LP increased its stake in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the period. Cadence Capital Management LLC increased its stake in shares of Humana by 0.4% in the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after purchasing an additional 22 shares during the period. Finally, Sit Investment Associates Inc. increased its stake in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 96.15% of the company’s stock.
In other news, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total value of $770,759.58. Following the transaction, the insider now directly owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Timothy S. Huval sold 7,803 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the transaction, the vice president now directly owns 8,831 shares in the company, valued at $2,279,634.34. The disclosure for this sale can be found here. Insiders sold a total of 20,660 shares of company stock worth $5,319,600 over the last three months. 0.80% of the stock is owned by company insiders.
Shares of Humana Inc. (NYSE:HUM) traded up $2.63 on Friday, hitting $235.91. The stock had a trading volume of 2,041,200 shares, compared to its average volume of 1,383,548. The firm has a market cap of $33,700.00, a P/E ratio of 19.90, a P/E/G ratio of 1.60 and a beta of 0.90. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana Inc. has a fifty-two week low of $186.25 and a fifty-two week high of $264.56.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping the consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $3.18 EPS. sell-side analysts anticipate that Humana Inc. will post 11.63 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is currently 12.60%.
A number of equities analysts have recently commented on the company. Credit Suisse Group dropped their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research note on Friday, November 10th. BMO Capital Markets lifted their price objective on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Morgan Stanley dropped their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a research note on Thursday, November 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $242.00 price objective (down from $245.00) on shares of Humana in a research note on Thursday, November 9th. Finally, Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Thirteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana presently has an average rating of “Hold” and a consensus price target of $252.81.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.